Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can big data defeat the ICU's deadliest foe?

NCT ID NCT07770347

Knowledge-focused Sponsor: Beijing Chao Yang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study follows thousands of critically ill patients in intensive care units across China to better understand sepsis, a life-threatening condition where the body's response to infection damages its own organs. Researchers will collect detailed information on infections, treatments, and patient outcomes to identify risk factors and develop tools for earlier detection and more personalized care. The goal is to reduce the high death rate and improve recovery for sepsis patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Individualized anti-infective therapy (antibiotics, antifungals) and immunomodulatory therapy (corticosteroids, immunoglobulins) as prescribed by the attending physician.
What this could lead to
If successful, this could lead to better early warning systems, more accurate diagnosis, and personalized treatment strategies for sepsis, potentially reducing its high death rate in ICUs.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove that any specific treatment works. The findings may not apply to other countries or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * ICU stay ≥ 24 hours * Informed consent signed by the patient or their legal representative Exclusion Criteria: * ICU stay \< 24 hours * Refusal to provide informed consent * Pregnancy or lactation * Receiving palliative care or expected survival \< 24 hours * Previously enrolled in this study * Severe immunodeficiency (HIV infection, or long-term use of corticosteroids/immunosuppressants)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Chao Yang Hospital

    Beijing, Beijing Municipality, 100020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.